In partnership with Revision Goodier’s leadership team, including CEO Maria Carell, Gryphon will continue to invest in the company’s mission of developing and delivering clinically proven and highly efficacious skincare products to a global customer base and advance the company’s contract development and manufacturing capabilities. Financial terms of the transaction were not disclosed. The transaction is expected to close in the fourth quarter of 2021.
For more than two decades, Revision Skincare has provided dermatologists, plastic surgeons and medical spas with clinically proven, high-performing skincare products. Using only premium quality ingredients, the Revision Skincare collection was formulated to provide targeted solutions for enhancing skin’s appearance and reducing signs of aging. Based in Irving, Texas, Revision Skincare is sold in more than 10 countries.
Since 1922, Irving, TX-based Goodier Cosmetics has been a trusted developer and manufacturer in cosmetic and OTC topical skincare solutions. Differentiated by an industry renowned Innovation Center of Excellence, Goodier, along with its team of R&D chemists, engineers and regulatory experts, remains at the forefront of market trends, new technologies, ingredients and advancements in formulation science, a media release explains.
“Revision has a unique position as a high-growth independent company in a compelling market. Skincare consumers are becoming more discerning about the products they use, and we are excited to invest in Revision’s mission to help bring carefully formulated and highly efficacious skincare products to a global customer base.”— Gryphon Operating Partner Mike Ferry
“We are thrilled to partner with Maria and her outstanding team to support Revision’s movement to bring scientific credibility, quality, innovation, and elegance to the professional skincare market. We are equally excited about the opportunity to build on Goodier’s differentiated capabilities and deliver world-class service to some of the fastest growing brands across the prestige beauty and personal care space.”— Eddie Douglas, Principal in Gryphon’s Consumer Group
“We are delighted to partner with the team at Gryphon as we enter our next phase of growth. Gryphon is an ideal partner given their knowledge of skincare, consumer health, and professionally-endorsed brands, and their investment will allow us to accelerate the incredible momentum we have built over the last few years.”— Revision Goodier CEO Maria Carell
“Revision Goodier represents a bullseye opportunity for Gryphon and leverages our proactive focus of investing behind leading efficacious skincare brands. We are proud to be partnering with the Revision Goodier management team, leaders in the clinical, efficacious skincare category, and to be supporting the team through their next phase of growth.”— Matt Farron, Partner and Head of Gryphon’s Consumer Group
Carell will continue to lead Revision Goodier’s management team. As part of the transaction, a number of Gryphon Executive Advisors will join Gryphon Operating Partner Mike Ferry, Gryphon Deal Partner Matt Farron, and Gryphon Principal Eddie Douglas on the Board of Directors. The transaction marks Gryphon’s third investment in skincare products and services and first investment in the physician dispensed skincare category, per the release.
[Source(s): Gryphon Investors, PR Newswire]